207 related articles for article (PubMed ID: 11715002)
21. Phosphomannomutase deficiency (PMM2-CDG): ataxia and cerebellar assessment.
Serrano M; de Diego V; Muchart J; Cuadras D; Felipe A; Macaya A; Velázquez R; Poo MP; Fons C; O'Callaghan MM; García-Cazorla A; Boix C; Robles B; Carratalá F; Girós M; Briones P; Gort L; Artuch R; Pérez-Cerdá C; Jaeken J; Pérez B; Pérez-Dueñas B
Orphanet J Rare Dis; 2015 Oct; 10():138. PubMed ID: 26502900
[TBL] [Abstract][Full Text] [Related]
22. Early fatal course in siblings with CDG-Ia (caused by two novel mutations in the PMM2 gene): clinical, molecular and autopsy findings.
Wurm D; Hänsgen A; Kim YJ; Lindinger A; Baghai A; Gortner L
Eur J Pediatr; 2007 Apr; 166(4):377-8. PubMed ID: 16941129
[No Abstract] [Full Text] [Related]
23. Hypolipidaemia among patients with PMM2-CDG is associated with low circulating PCSK9 levels: a case report followed by observational and experimental studies.
Chong M; Yoon G; Susan-Resiga D; Chamberland A; Cheillan D; Paré G; Seidah NG
J Med Genet; 2020 Jan; 57(1):11-17. PubMed ID: 31391289
[TBL] [Abstract][Full Text] [Related]
24. Primary ovarian insufficiency in a female with phosphomannomutase-2 gene (PMM2) mutations for congenital disorder of glycosylation.
Masunaga Y; Mochizuki M; Kadoya M; Wada Y; Okamoto N; Fukami M; Kato F; Saitsu H; Ogata T
Endocr J; 2021 May; 68(5):605-611. PubMed ID: 33583911
[TBL] [Abstract][Full Text] [Related]
25. Liposome-encapsulated mannose-1-phosphate therapy improves global N-glycosylation in different congenital disorders of glycosylation.
Budhraja R; Radenkovic S; Jain A; Muffels IJJ; Ismaili MHA; Kozicz T; Pandey A; Morava E
Mol Genet Metab; 2024 Jun; 142(2):108487. PubMed ID: 38733638
[TBL] [Abstract][Full Text] [Related]
26. Clinical phenotype correlates to glycoprotein phenotype in a sib pair with CDG-Ia.
Barone R; Sturiale L; Sofia V; Ignoto A; Fiumara A; Sorge G; Garozzo D; Zappia M
Am J Med Genet A; 2008 Aug; 146A(16):2103-8. PubMed ID: 18629883
[TBL] [Abstract][Full Text] [Related]
27. Genotypes and estimated prevalence of phosphomannomutase 2 deficiency in Turkey differ significantly from those in Europe.
Yıldız Y; Arslan M; Çelik G; Kasapkara ÇS; Ceylaner S; Dursun A; Sivri HS; Coşkun T; Tokatlı A
Am J Med Genet A; 2020 Apr; 182(4):705-712. PubMed ID: 31981409
[TBL] [Abstract][Full Text] [Related]
28. Glycomic Characterization of Induced Pluripotent Stem Cells Derived from a Patient Suffering from Phosphomannomutase 2 Congenital Disorder of Glycosylation (PMM2-CDG).
Thiesler CT; Cajic S; Hoffmann D; Thiel C; van Diepen L; Hennig R; Sgodda M; Weiβmann R; Reichl U; Steinemann D; Diekmann U; Huber NM; Oberbeck A; Cantz T; Kuss AW; Körner C; Schambach A; Rapp E; Buettner FF
Mol Cell Proteomics; 2016 Apr; 15(4):1435-52. PubMed ID: 26785728
[TBL] [Abstract][Full Text] [Related]
29. Congenital disorder of glycosylation type Ia in a Malaysian family: clinical outcome and description of a novel PMM2 mutation.
Thong MK; Fietz M; Nicholls C; Lee MH; Asma O
J Inherit Metab Dis; 2009 Dec; 32 Suppl 1():S41-4. PubMed ID: 19165618
[TBL] [Abstract][Full Text] [Related]
30. Sorbitol Is a Severity Biomarker for PMM2-CDG with Therapeutic Implications.
Ligezka AN; Radenkovic S; Saraswat M; Garapati K; Ranatunga W; Krzysciak W; Yanaihara H; Preston G; Brucker W; McGovern RM; Reid JM; Cassiman D; Muthusamy K; Johnsen C; Mercimek-Andrews S; Larson A; Lam C; Edmondson AC; Ghesquière B; Witters P; Raymond K; Oglesbee D; Pandey A; Perlstein EO; Kozicz T; Morava E
Ann Neurol; 2021 Dec; 90(6):887-900. PubMed ID: 34652821
[TBL] [Abstract][Full Text] [Related]
31. Three families with mild PMM2-CDG and normal cognitive development.
Vals MA; Morava E; Teeäär K; Zordania R; Pajusalu S; Lefeber DJ; Õunap K
Am J Med Genet A; 2017 Jun; 173(6):1620-1624. PubMed ID: 28425223
[TBL] [Abstract][Full Text] [Related]
32. [Clinical and genetic analysis for two children with congenital disturbance of glycosylation with PMM2 gene mutations].
Ren C; Fang F; Huang Y; Cheng H; Dai L
Zhonghua Er Ke Za Zhi; 2015 Dec; 53(12):938-42. PubMed ID: 26887550
[TBL] [Abstract][Full Text] [Related]
33. Lack of homozygotes for the most frequent disease allele in carbohydrate-deficient glycoprotein syndrome type 1A.
Matthijs G; Schollen E; Van Schaftingen E; Cassiman JJ; Jaeken J
Am J Hum Genet; 1998 Mar; 62(3):542-50. PubMed ID: 9497260
[TBL] [Abstract][Full Text] [Related]
34. Mild clinical and biochemical phenotype in two patients with PMM2-CDG (congenital disorder of glycosylation Ia).
Casado M; O'Callaghan MM; Montero R; Pérez-Cerda C; Pérez B; Briones P; Quintana E; Muchart J; Aracil A; Pineda M; Artuch R
Cerebellum; 2012 Jun; 11(2):557-63. PubMed ID: 22012410
[TBL] [Abstract][Full Text] [Related]
35. Borderline mental development in a congenital disorder of glycosylation (CDG) type Ia patient with multisystemic involvement (intermediate phenotype).
Barone R; Sturiale L; Fiumara A; Uziel G; Garozzo D; Jaeken J
J Inherit Metab Dis; 2007 Feb; 30(1):107. PubMed ID: 17186415
[TBL] [Abstract][Full Text] [Related]
36. AZATAX: Acetazolamide safety and efficacy in cerebellar syndrome in PMM2 congenital disorder of glycosylation (PMM2-CDG).
Martínez-Monseny AF; Bolasell M; Callejón-Póo L; Cuadras D; Freniche V; Itzep DC; Gassiot S; Arango P; Casas-Alba D; de la Morena E; Corral J; Montero R; Pérez-Cerdá C; Pérez B; Artuch R; Jaeken J; Serrano M;
Ann Neurol; 2019 May; 85(5):740-751. PubMed ID: 30873657
[TBL] [Abstract][Full Text] [Related]
37. Novel Treatment for Congenital Disorder of Glycosylation in a Patient with Novel Homozygote Mutation of PMM2: A Case Report and Review Literature.
Madani S; Sayarifard F; Tajdini P; Mohsenipour R; Khoram Khorshid HR; Rezaei N
Endocr Metab Immune Disord Drug Targets; 2021; 21(12):2296-2299. PubMed ID: 33858316
[TBL] [Abstract][Full Text] [Related]
38. A novel PMCA3 mutation in an ataxic patient with hypomorphic phosphomannomutase 2 (PMM2) heterozygote mutations: Biochemical characterization of the pump defect.
Vicario M; Calì T; Cieri D; Vallese F; Bortolotto R; Lopreiato R; Zonta F; Nardella M; Micalizzi A; Lefeber DJ; Valente EM; Bertini E; Zanotti G; Zanni G; Brini M; Carafoli E
Biochim Biophys Acta Mol Basis Dis; 2017 Dec; 1863(12):3303-3312. PubMed ID: 28807751
[TBL] [Abstract][Full Text] [Related]
39. Clinical and molecular diagnosis of non-phosphomannomutase 2 N-linked congenital disorders of glycosylation in Spain.
Medrano C; Vega A; Navarrete R; Ecay MJ; Calvo R; Pascual SI; Ruiz-Pons M; Toledo L; García-Jiménez I; Arroyo I; Campo A; Couce ML; Domingo-Jiménez MR; García-Silva MT; González-Gutiérrez-Solana L; Hierro L; Martín-Hernández E; Martínez-Pardo M; Roldán S; Tomás M; Cabrera JC; Mártinez-Bugallo F; Martín-Viota L; Vitoria-Miñana I; Lefeber DJ; Girós ML; Serrano Gimare M; Ugarte M; Pérez B; Pérez-Cerdá C
Clin Genet; 2019 May; 95(5):615-626. PubMed ID: 30653653
[TBL] [Abstract][Full Text] [Related]
40. GPI-anchor and GPI-anchored protein expression in PMM2-CDG patients.
de la Morena-Barrio ME; Hernández-Caselles T; Corral J; García-López R; Martínez-Martínez I; Pérez-Dueñas B; Altisent C; Sevivas T; Kristensen SR; Guillén-Navarro E; Miñano A; Vicente V; Jaeken J; Lozano ML
Orphanet J Rare Dis; 2013 Oct; 8():170. PubMed ID: 24139637
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
